×

Intellectual Property Patents

  • WASHINGTON, Jan 18- The U.S. International Trade Commission said on Wednesday it had launched on investigation into whether Fujifilm Holdings Corp was violating patents which Sony Corp holds for certain magnetic tape cartridges.

  • WASHINGTON, Jan 17- The U.S. Federal Trade Commission filed a lawsuit against Qualcomm Inc on Tuesday, accusing the company of using "anticompetitive" tactics to maintain its monopoly on a key semiconductor used in mobile phones. The FTC, which works with the Justice Department to enforce antitrust law, said that San Diego- based Qualcomm used its dominant...

  • WASHINGTON, Jan 17- The U.S. Federal Trade Commission filed a lawsuit against Qualcomm Inc on Tuesday, accusing the company of using "anticompetitive" tactics to maintain its monopoly on a key semiconductor used in mobile phones. The FTC, which works with the Justice Department to enforce antitrust law, said that San Diego- based Qualcomm used its dominant...

  • WASHINGTON, Jan 17- The U.S. Federal Trade Commission filed a lawsuit against Qualcomm Inc on Tuesday, accusing the company of antitrust violations in its patent licensing business. The FTC asked the U.S. District Court for the Northern District of California in San Jose to order Qualcomm to cease this and related practices. In February 2015, Qualcomm paid a $975...

  • Jan 17- Biogen Inc said on Tuesday it would pay Forward Pharma A/S $1.25 billion in cash to license the Danish company's patents covering multiple sclerosis drugs including Biogen's flagship drug, Tecfidera. "We believe this agreement will clarify and strengthen our intellectual property for Tecfidera," said Biogen Chief Executive Michel Vounatsos said in a...

  • Jan 9- Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out. Speaking at the annual JP Morgan Healthcare Conference in San Francisco, Schleifer said Amgen had refused a request to...

  • Jan 9- Regeneron Pharmaceuticals Chief Executive Len Schliefer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out. Speaking at the annual JP Morgan Healthcare Conference in San Francisco, Schliefer said Amgen had refused a request to...

  • Jan 5- Regeneron Pharmaceuticals Inc and Sanofi SA said on Thursday they would appeal the U.S. District Court ruling which banned the two companies from selling their cholesterol drug, Praluent, on grounds of patent infringement. District Judge Sue Robinson in Delaware had ordered that the ban not take effect for 30 days to give Sanofi and Regeneron time to...

  • In an October 2014 lawsuit, Amgen had sought to stop Paris- based Sanofi and Tarrytown, New York- based Regeneron from selling Praluent, a drug intended to lower bad LDL cholesterol by blocking a protein known as PCSK9. Amgen makes a rival drug called Repatha, and it said Praluent infringed the Thousand Oaks, California- based company's patents related to the...

  • In an October 2014 lawsuit, Amgen had sought to stop Paris- based Sanofi and Tarrytown, New York- based Regeneron from selling Praluent, a drug intended to lower bad LDL cholesterol by blocking a protein known as PCSK9. Amgen makes a rival drug called Repatha, and it said Praluent infringed the Thousand Oaks, California- based company's patents related to the...

  • Merck awarded $2.54B in patent suit against Gilead

    The pharmaceutical company wins its hepatitis C drug trial against Gilead Sciences.

  • Harvoni

    Merck was awarded $2.54 billion in royalties by a jury in a patent lawsuit against Gilead Sciences over Gilead's hepatitis C drugs.

  • Facebook patenting tool to remove fake news from site

    The social media giant plans to stop the spread of misinformation by using systems and methods to identify objectionable content on its site.

  • Supreme Court sides with Samsung in Apple patent case

    The US Supreme Court ruled for the South Korean company in a dispute over damages related to Apple's iPhone design.

  • Court makes key ruling on insider trading cases

    CNBC's Hampton Pearson reports on two decisions from the Supreme Court regarding insider trading and patent infringement.

  • CNBC unveils new intelligence index

    CNBC's Dominic Chu introduces the CNBC IQ 100 - an index which contains a collection of companies that derive substantial revenue from intellectual property.

  • The fierce, big-money patent fight between Apple and Samsung left the U.S. Supreme Court groping for a solution on Tuesday.

  • Apple vs. Samsung case hits Supreme Court

    CNBC's Hampton Pearson reports the latest on the Apple/Samsung patent case being heard at the Supreme Court.

  • Price of innovation in pharma: Pro

    Kevin Sharer, Harvard Business School, discusses competition in the pharmaceutical industry and balancing drug prices and profits.

  • How Xiaomi is navigating the smartphone war

    Hugo Barra, VP of Xiaomi Global, talks about how the company engages customers in India, and its development of a patent and IP war chest.